New York investors have completed their acquisition of San Diego drugmaker Cypress Bioscience, which had been a publicly held company, a spokesman for the new owners said Thursday. The acquisition by the hedge fund Ramius and drug company Royalty Pharma closed Jan. 13 for the previously disclosed price of $6.50 a share, or about $255 million, said Peter Feld with Ramius. News